Empower Clinics Kai Medical Laboratory Secures COVID-19 Testing Contract For Large Gaming Event In Las Vegas

3 years ago

Kai Medical Laboratory to Provide Over 6,000 Rapid Antigen and PCR COVID-19 TestsVANCOUVER, BC / ACCESSWIRE / December 13, 2021…

Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome

3 years ago

Pivotal clinical trial will begin in first half of 2022ENGLEWOOD, CO / ACCESSWIRE / December 13, 2021 / Aytu BioPharma,…

Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases

3 years ago

JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1…

StageZero Life Sciences Named a COVID-19 Travel Testing Partner for Aruba

3 years ago

Teams up with OK2Roam and VFS Global to streamline COVID-19 testing protocols for travelers from Canada and the U.S.TORONTO, ON…

Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary

3 years ago

ORLANDO, FL / ACCESSWIRE / December 13, 2021 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of pharmaceutical…

Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM Effective

3 years ago

Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes EffectiveABINGDON, OXFORDSHIRE / ACCESSWIRE / December 13,…

Senti Bio Highlights Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting

3 years ago

- Preclinical data demonstrates complete functionality of SENTI-202 OR+NOT Logic Gated gene circuits for the elimination of AML cancer cells…

Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

3 years ago

B-AMAZE long-term follow up data demonstrate sustained FIX expression up to 3.5 years; potential for expression levels in the normal…